Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px
Document › Details

Thermo Fisher Scientific Inc.. (10/25/18). "Press Release: Thermo Fisher Scientific Completes Acquisition of Advanced Bioprocessing from BD". Waltham, MA.

Organisations Organisation Thermo Fisher Scientific Inc. (NYSE: TMO)
  Group Thermo Fisher (Group)
  Organisation 2 Becton, Dickinson & Co. (NYSE: BDX)
  Group Becton, Dickinson (Group)
Product Product  laboratory equipment and instruments
Index term Index term Becton Dickinson–Thermo Fisher: investment, 201810 acquisition $477m in cash of BD Advanced Bioprocessing business by Thermo Fisher
Persons Person Stevenson, Mark (Thermo Fisher 201402– EVP + President Life Sciences Solutions before Life Technologies COO)
  Person 2 O’Brien, Ron (Thermo Fisher 201003 Director Public Relations)
     


Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today completed its previously announced acquisition of the Advanced Bioprocessing business from BD (Becton, Dickinson and Company – NYSE: BDX), a leading global medical technology company, for $477 million in cash, subject to post-closing adjustments. The business will be integrated into Thermo Fisher's Life Sciences Solutions Segment.

The Advanced Bioprocessing business has annualized revenue of approximately $100 million, with 160 employees at principal manufacturing locations in Detroit, Mich. and Miami, Fla.

"We are pleased to complete this acquisition and officially welcome our new colleagues from BD to Thermo Fisher," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "The addition of Advanced Bioprocessing's complementary cell-culture media products and strong technical services program into our leading bioproduction portfolio will enable our biopharmaceutical customers to bring new and innovative drugs to market faster."

The Advanced Bioprocessing acquisition is expected to add revenue of approximately $15 million in 2018, with no impact on adjusted earnings per share (EPS). For 2019, the company expects $0.04 to $0.05 of adjusted EPS accretion.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com


Media Contact Information:

Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com

or

Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com

   
Record changed: 2018-11-03

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Thermo Fisher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px




» top